BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Govt supports indigenous manufacturing of complex pharma excipients by Nitika Pharmaceutical Specialties

03 June 2025 | News

For commercial-scale production of 14 complex excipients



The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India has extended financial support to Nitika Pharmaceutical Specialties Private Limited, Nagpur, for their project titled“Manufacture of Complex Excipients.”

Excipients, though pharmacologically inactive, are critical to the functionality, stability, and delivery of medicines. As drug formulations become increasingly sophisticated—with the rise of complex generics, biopharmaceuticals, and novel delivery systems—the demand for high-quality, tailor-made excipients has surged globally.

Through this project, Nitika Pharmaceutical Specialties aims to establish a state-of-the-art manufacturing facility for commercial-scale production of 14 complex excipients that cater to advanced pharmaceutical applications.

These products will be developed in line with the Quality by Design (QbD) framework, ensuring precision in parameters like surface area, particle size, and stability to meet international standards.

Established in 1991 and later incorporated as a Private Limited Company in 2011, Nitika has evolved into a trusted global supplier of fine chemicals and specialty excipients. With a DSIR-recognised in-house R&D facility and a global footprint across 90 countries, the company is well-positioned to translate this project into a significant leap toward self-reliance in pharma auxiliary production.

The project is also aligned with the Government of India’s Production Linked Incentive (PLI) scheme for pharmaceuticals, under which Nitika has been selected as a beneficiary under Group C – MSME (Pharmaceuticals). TDB’s support complements the broader national mission of fostering indigenous manufacturing, reducing import dependency, and expanding India’s export potential in high-value pharmaceutical components.